Day: August 4, 2020

VANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), an emerging leader in augmented reality for eCommerce, AR learning applications, and AR-enhanced video conferencing and virtual events is pleased to announce it has been selected to provide the InfernoAR platform, ScreenAR, and event design services for CREVOLUTION 2020 from ICM Credit in Mexico November 10 – 12, 2020. The initial value of the contract is $90,000 with the potential for additional revenue through the sale of augmented reality booths, and ‘ScreenAR’ services.Luis Eduardo Perez, President, ICM Credit comments, “Crevolution is the most disruptive event in the global financial industry, when moving to a digital environment, we had the need to maintain that innovative spirit in...

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation at the 2020 Wedbush PacGrow Healthcare Virtual Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company on Tuesday, August 11, 2020 at 2:20 p.m. ET / 11:20 a.m. PT. The virtual conference will be held from August 11-12, 2020.A live audio webcast of the presentation will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay available for 30 days following the event.About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise...

WALTHAM, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for ELX-02 for the treatment of Cystic Fibrosis.The FDA’s Office of Orphan Drug Products grants orphan status to support the development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S. Orphan-drug designation qualifies Eloxx for certain benefits, including seven years of market exclusivity upon regulatory approval if received, exemption...

IRVINE, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — Lantronix, Inc. (the “Company”) (Nasdaq: LTRX), a global provider of secure data access and management solutions for the industrial Internet of Things (IoT), today announced its fall 2020 investor conference schedule. Lantronix CEO Paul Pickle and CFO Jeremy Whitaker will participate in the following virtual conferences:Canaccord Genuity 40th Annual Growth Conference: Aug. 11–13, 2020Management will host one-on-one meetings as well as participate in a fireside chat presentation on Aug. 13th at 9:00 a.m. EDT. Details for the telecast will be available on the Lantronix Investor Relations page. To book a one-on-one meeting, please contact your Canaccord Genuity salesperson or visit the event page.Oppenheimer 23rd Annual Virtual Technology, Internet & Communications Conference: Aug....

Philadelphia, PA, Aug. 04, 2020 (GLOBE NEWSWIRE) — VSBLTY Groupe Technologies Corp. (CSE: VSBY) (Frankfurt: 5VS) (OTC: VSBGF) (“VSBLTY”), a leading provider of security and retail marketing technology, and its Mexico partner Retailigent Media have been contracted to provide advanced audience analytics and customer engagement technology in a Mexican chain of pet stores, it was announced today by VSBLTY Co-founder & CEO Jay Hutton.Retailigent Media, with offices in Mexico and five other Latin American countries, is the leading company in Mexico for smart retail solutions, analytics and smart displays. Retailigent provides advertising and marketing insights to some of the world’s leading brands, including P&G, Coca Cola, Diageo and Telefonica. The company specializes in providing brands and retailers with personalized shopping...

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Aug. 04, 2020 (GLOBE NEWSWIRE) — Norseman Capital Ltd. (NEX:NOC.H) (“Norseman” or the “Company”) is pleased to announce a proposed non-brokered private placement financing of units (“Units”) of the Company (the ”Offering”) at a price of CAD$0.15 per Unit for gross proceeds of up to CAD$300,000. Each Unit shall be composed of one common share (“Share”) and one-half of one Share purchase warrant (“Warrant”). Each whole Warrant shall entitle the holder to purchase one Share at a price of CAD$0.25 per Share for a period of twenty-four months from the date of issuance. Closing of the Offering is expected to occur on or around August...

ALPHARETTA, Ga., Aug. 04, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020 at 9:10 a.m. ET.A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated...

SANTA CLARA, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) — Inphi Corporation (NYSE: IPHI), a leader in high-speed data movement interconnects, today announced financial results for its second quarter ended June 30, 2020.GAAP ResultsRevenue in the second quarter of 2020 was a record $175.3 million on a U.S. generally accepted accounting principles (GAAP) basis, up 103.2% year-over-year, compared with $86.3 million in the second quarter of 2019. The increase was due to higher demand for Cloud and Telecommunications products as well as the inclusion of eSilicon revenues as a result of the acquisition that closed on January 10, 2020.Gross margin under GAAP in the second quarter of 2020 was 53.0%, compared with 56.9% in the second quarter of 2019. The decrease was mainly due to amortization of intangibles, step up value of inventories related...

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020:BTIG Virtual Biotechnology Conference 2020 on Monday, August 10, 2020 at 11:30 a.m. ET2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:55 a.m. ETTo access live and archived webcasts of the presentations, please visit the Events & Presentations page of the G1 website.About G1 TherapeuticsG1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage...

DALLAS, Aug. 04, 2020 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL) an SEC fully-reporting, growth-oriented manufacturing and marketing company focused on employing FDA-approved Metered Dose Inhaler (MDI) technology to deliver aerosolized cannabinoids, such as CBD, CBG, and CBN, announces that it has formally engaged FDA Compliance Solutions, LLC to begin the initial FDA regulatory process of registering their new facilities and ultimately all products. FDA Compliance Solutions, LLC will act as RTSL’s agent through the entire registration process. FDA Compliance Solutions submitted RTSL’s initial filing required by the FDA in May 2020.This registration process will establish the initial account and fulfill preliminary FDA compliance notification requirements by documenting current domestic manufacturing...